Drugs / CLIO-8221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07300943 | Mar 2026 → Dec 2027 expected | neoplasm | Callio Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLIO-8221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300943 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT07300943 ↗ |